In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Retrophin gets exclusive global rights to DARA from Ligand

Executive Summary

Ligand Pharmaceuticals Inc. (acquires products and then out-licenses them in order to gain a steady stream of royalties) has sublicensed Retrophin LLC (developing therapeutics for rare and life-threatening diseases) exclusive global rights to the DARA (Dual Acting Receptor Antagonist) PS433540 program. DARA acts as both an angiotensin receptor blocker and a selective endothelin receptor antagonist for receptor type A.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register